Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags CC transcript
|
SINOVAC BIOTECH LTD (SVA)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/15/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/01/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
04/28/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
02/22/2023 |
6-K
| Quarterly results |
12/29/2022 |
6-K
| Quarterly results |
11/04/2022 |
6-K
| Quarterly results |
06/09/2022 |
6-K
| Quarterly results |
05/06/2022 |
6-K
| Quarterly results |
04/29/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
02/22/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/30/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/13/2021 |
6-K
| Quarterly results |
12/10/2021 |
6-K
| Quarterly results |
12/07/2021 |
6-K
| Quarterly results |
11/10/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Preliminary Results Show SINOVAC’ s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population BEIJING, China, November 9, 2021 -- SINOVAC Biotech Ltd. , a leading provider of biopharmaceutical products in China, announced new preliminary data on its inactivated COVID-19 vaccine CoronaVac®. The results from statistics analysis under blind status indicated that CoronaVac® is safe for healthy people of different races in the pediatric and adolescent population ranging from 3 to 17 years of age. The multi-center, case-driven, randomized, double-blind, and placebo-controlled phase III study is currently being conducted in South Africa, Chile, Malaysia, and the Philippines. As of October 2021, a total of 2,140 participants ranging from 6 months to 17 years o..." |
|
07/20/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
07/20/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
07/12/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
06/30/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
06/02/2021 |
6-K
| Quarterly results |
04/22/2021 |
6-K
| Quarterly results |
04/02/2021 |
6-K
| Quarterly results |
02/22/2021 |
6-K
| Quarterly results |
02/08/2021 |
6-K
| Quarterly results |
12/09/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/07/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
09/29/2020 |
6-K
| Quarterly results |
09/23/2020 |
6-K
| Quarterly results |
09/23/2020 |
6-K
| Quarterly results |
08/28/2020 |
6-K
| Quarterly results |
08/26/2020 |
6-K
| Quarterly results |
07/06/2020 |
6-K
| Quarterly results |
06/30/2020 |
6-K
| Quarterly results |
06/24/2020 |
6-K
| Quarterly results |
|
|
|